Theralase Technologies Inc. announced a non brokered private placement to issue units at an issue price of CAD 0.22 per unit on July 8, 2024. Each Unit consists of one common share and one common share purchase warrant. Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of CAD 0.30 per share for a period of 5 years following the date of issuance.

On the same date, the company announced that it has issued an aggregate of 3,522,729 Units at a price of CAD 0.22 per for aggregate gross proceeds of CAD 775,000.38 in first tranche. Each Unit consists of one common share and one common share purchase warrant. Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of CAD 0.30 per share for a period of 5 years following the date of issuance. All securities issued under the Offering will be subject to a four month and one day hold period from the closing date under applicable Canadian securities laws, which expires on November 6th, 2024. The Offering is subject to receipt of final acceptance from the TSX Venture Exchange.